Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Happy to share our poster at ESMOGI25 in Barcelona on G/GEJ cancer trials – endpoints and global trends. Interesting to see how Asia, especially China, is now leading in both early and late-phase trials. Many late-stage studies still rely on surrogate endpoints, and pharma-sponsored trials show higher discontinuation rates.
And of course, haven’t lost the chance to reconnect with my mentor Yelena Janjigian, get some inspiration, and meet experts and friends from around the world.
Thank you, European School of Oncology, for supporting to be here!”
More posts featuring Amalya Sargsyan.
